This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Patel KK, et al. Cost-Effectiveness of First-Line Ibrutinib versus Third-Line in Patients with Untreated Chronic Lymphocytic Leukemia. Blood : 9 Jun 2020. Available from: URL: https://doi.org/10.1182/blood.2020004922
About this article
Cite this article
First-line ibrutinib in untreated CLL: QOL improvement at high cost. PharmacoEcon Outcomes News 856, 16 (2020). https://doi.org/10.1007/s40274-020-6916-0